Implications of Mutation Profiling in Myeloid Malignancies —PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Hematologic Malignancies Myeloproliferative Neoplasms Oncology Journal Review Article Source Type: news
Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia
A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Myeloproliferative Neoplasms News Source Type: news
How blood cancers outsmart the immune system
(American Association for the Advancement of Science) Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2018 Category: Cancer & Oncology Source Type: news
MPN Patients See Increased Rate of Arterial, Venous Thrombosis (CME/CE)
(MedPage Today) -- Highest rates at and shortly after diagnosis of myeloproliferative neoplasms (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 16, 2018 Category: Cardiology Source Type: news
' Eye-opening' Study on Rates of Thrombosis With MPNs'Eye-opening' Study on Rates of Thrombosis With MPNs
For the first time, a population-based study has assessed the rates of thrombotic events in patients with myeloproliferative neoplasms (MPNs).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Mutational Profiles of Primary Myelofibrosis and Other MPNs Mutational Profiles of Primary Myelofibrosis and Other MPNs
This study analyzed the mutational profiles and cytogenetic abnormalities of three common chronic myeloproliferative neoplasms, with the aim of facilitating diagnosis between them.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms. (Source: CancerNetwork)
Source: CancerNetwork - July 15, 2017 Category: Cancer & Oncology Authors: Leslie Padrnos, MD Ruben A. Mesa, MD Tags: Hematologic Malignancies Oncology Journal Review Article Source Type: news
FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news
Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms
Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
UT Health taps new leader for San Antonio cancer center
UT Health San Antonio has selected Dr. Ruben A. Mesa to serve as director of its UT Health Cancer Center.
Mesa is currently professor of medicine and chair of the Division of Hematology& Medical Oncology at the Mayo Clinic in Arizona. He is also deputy director of the Mayo Clinic Cancer Center.
UT Health San Antonio President Dr. William Henrich said Mesa is an international expert on myeloproliferative neoplasms, a group of bone marrow disorders that often lead to leukemia.
Mesa has been a principal… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 13, 2017 Category: Biotechnology Authors: W. Scott Bailey Source Type: news
UT Health taps new leader for San Antonio cancer center
UT Health San Antonio has selected Dr. Ruben A. Mesa to serve as director of its UT Health Cancer Center.
Mesa is currently professor of medicine and chair of the Division of Hematology& Medical Oncology at the Mayo Clinic in Arizona. He is also deputy director of the Mayo Clinic Cancer Center.
UT Health San Antonio President Dr. William Henrich said Mesa is an international expert on myeloproliferative neoplasms, a group of bone marrow disorders that often lead to leukemia.
Mesa has been a principal… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 13, 2017 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news
Mayo Clinic PathWays: What's the diagnosis?
This week's case study reviews the bone marrow biopsy and myeloproliferative neoplasm ??malignant disease associated with increased production of blood cells ??workup from a 60-year-old woman who presented with two years of progressive transfusion-dependent anemia. Can you make the diagnosis? View the case and make your diagnosis. Learn more about Mayo Clinic PathWays. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2017 Category: Databases & Libraries Source Type: news
Overview of Myeloproliferative Disorders
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2017 Category: Cancer & Oncology Authors: Srdan Verstovsek, MD, PhD Tags: Hematologic Malignancies Conferences/ICHM 2017 News Source Type: news
Outlook for 2017: Myeloma, Lymphoma, and MPNs
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms. (Source: CancerNetwork)
Source: CancerNetwork - December 23, 2016 Category: Cancer & Oncology Authors: Amrita Y. Krishnan, MD David Snyder, MD Robert Chen, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news
Novel Germline Mutations in the Calreticulin Gene Novel Germline Mutations in the Calreticulin Gene
The authors identify germline mutations in the calreticulin gene which differ from those that define classic myeloproliferative neoplasms. What might their role be in the etiology of these disorders?Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
